{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:05:58Z","timestamp":1790366758304,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.07.021","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:26:39Z","timestamp":1784179599000},"page":"1744-1750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients"],"prefix":"10.1016","volume":"20","author":[{"given":"Robert P.","family":"Giugliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Marston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.07.021_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.07.021_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.07.021_bib3","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.07.021_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.07.021_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MOL.0000000000000830","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction","volume":"33","author":"Schwartz","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.021_bib6","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.jacc.2025.10.036","article-title":"Obesity-associated cardiovascular risk and benefit from PCSK9 inhibition:\u00a0a prespecified analysis from FOURIER","volume":"87","author":"Kang","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.07.021_bib7","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1161\/CIRCULATIONAHA.124.072756","article-title":"Intensive lowering of LDL cholesterol levels with evolocumab in autoimmune or inflammatory diseases: an analysis of the FOURIER trial","volume":"151","author":"Zimerman","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.07.021_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacl.2026.02.006","article-title":"Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: a meta-analysis","volume":"20","author":"Kalra","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.021_bib9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2026.3277","article-title":"Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial","volume":"335","author":"Marston","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.07.021_bib10","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.07.021_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.021_bib12","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.jacc.2026.02.4869","article-title":"Clinical guidelines as a continuous work in progress: moving at the speed of science","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.1016\/j.jacl.2026.07.021_bib13","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2026.07.021_bib14","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:57:37Z","timestamp":1790366257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1933287426004502"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.021","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}